Clinical Trials Logo

Clinical Benefit Rate clinical trials

View clinical trials related to Clinical Benefit Rate.

Filter by:
  • None
  • Page 1

NCT ID: NCT03359018 Completed - Toxicity Clinical Trials

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

APFAO
Start date: January 1, 2018
Phase: Phase 2
Study type: Interventional

After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades. We have already finished a prospective trial about apatinib for advanced osteosarcoma(NCT02711007) and find it has a objective response rate of aproximately 45% with median progression-free survival around 5 months. Thus, the investigators explored apatinib activity together with anti-PD1 therapy in order to induce durable response in patients with relapsed and unresectable osteosarcoma after the failure of first-line or second-line chemotherapy. Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor, similar to pazopanib, but with a binding affinity 10 times to VEGFR-2 comparing with pazopanib or sorafenib. SHR-1210 is a humanized anti-PD-1 monoclonal antibody.